<DOC>
	<DOCNO>NCT00003429</DOCNO>
	<brief_summary>RATIONALE : New image procedure fludeoxyglucose F 18 PET scan may improve ability detect cancer recurrence cancer . PURPOSE : Clinical trial study effectiveness fludeoxyglucose F 18 PET scan diagnose primary recurrent cervical cancer patient undergo surgery .</brief_summary>
	<brief_title>PET Scans Diagnosing Primary Recurrent Cervical Cancer Patients Who Are Undergoing Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Assess feasibility use fludeoxyglucose F 18 ( FDG ) positron emission tomography ( PET ) image patient primary recurrent cervical cancer . - Investigate ability FDG-PET scan imaging detect lymph node metastases patient . - Investigate ability FDG-PET imaging identify locally advance disease early stage cervical cancer . - Compare FDG-PET CT scan imaging respect distinguish postradiation pelvic fibrosis recurrent cervical cancer . - Investigate ability FDG-PET identify recurrent cervical cancer . OUTLINE : This diagnostic study . Patients primary cervical cancer receive fludeoxyglucose F 18 ( FDG ) intravenously follow 45 minute later positron emission tomography ( PET ) image 60 minute , well compute tomography ( CT ) scan . Both diagnostic imaging technique assess abdomen pelvis , must do within 2 week prior surgery . Patients eligible surgery undergo radical hysterectomy lymphadenectomy specimen evaluate correlation preoperative diagnostic test finding . Patients recurrent cervical cancer obtain FDG-PET scan CT scan thorax , abdomen , pelvis prior surgical exploration pelvic exenteration . All biopsy specimen evaluate correlation diagnostic test finding . PROJECTED ACCRUAL : A total 30 patient ( 20 patient primary cervical cancer 10 patient recurrent cervical cancer ) accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must meet one follow criterion : Histologically confirm primary invasive squamous carcinoma adenocarcinoma cervix History cervical cancer suspect recurrent Known diagnosis recurrent cervical cancer consider pelvic exenteration PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No insulindependent diabetes mellitus No active serious infection control antibiotic Must tolerate scanner duration study Not mentally retarded No prisoner Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stage I cervical cancer</keyword>
	<keyword>stage II cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
</DOC>